Navigation Links
New Moffitt Cancer Center patent promises to accelerate cancer trials
Date:2/14/2012

TAMPA, Fla. A new patent has been issued to Moffitt Cancer Center for a computerized system that efficiently selects the right patient for the right clinical trial. The newly patented system matches the registered patient's own molecular profile warehoused in a database of thousands of patient-donated biological tissue or tumor samples to the molecular design of the drug aimed at targeting their disease at the molecular level, and does it quickly. The system promises to accelerate clinical trials and help shorten the time that it takes to get critically needed new drugs into the market.

Getting new drugs to market to fight cancer and other serious diseases requires, on average, 15 years. The drug development process is long and complex, but the three-phase clinical trials process estimated to take up to half of those 15 years is often the bottleneck in getting innovative drugs to the patients who need them.

Clinical trials, increasingly becoming more expensive, are also multifaceted. While patients may qualify for a clinical trial based on their age or stage of disease, they may not be, over the long term of the trial, the best candidates to test a drug. Adverse events, changes in a patient's health status and the potential for a drug not being effective for them slow the process. Although patients may have met the trial protocol's criteria, the drug may not be right for them because their molecular profile is not a good match for the chemical and molecular properties of the drug.

Because the concept of personalized medicine is selecting the right drug for the right patient, innovations have been needed to bring personalized medicine to reality. Personalizing the selection process for clinical trials is a vital step.

With the development of new and better ways to examine and understand a tumor's molecular profile, matching the right patient to the right clinical trial becomes increasingly important. But handling the massive data evaluation necessary to accomplish this has been a stumbling block.

The newly patented computer system, Patent Number US 8,095,389 B2, or "Computer Systems and Methods for Selecting Patients for Clinical Trials," is designed to surmount that problem.

The newly patented computer system is designed to:

  • Select patients to clinical trials matching an individual's/drug's molecular profile
  • Match patients to clinical trials by a patient's disease/diagnosis
  • Match patients to clinical trials by their symptoms
  • Match patients to clinical trials by their demographic information and family history
  • Track a clinical trial participant's disease progression compared to drug efficacy

The newly patented computer system and associated products, such as operating system, software, interfaces and data retrieval system, improve clinical trial selection efficacy by making the patient selection process less random and more selective. The technology has the potential to refine clinical trials by eliminating bottlenecks, overhauling the selection process and shortening the timeline, ultimately bringing new drugs to market more efficiently.


'/>"/>
Contact: Michelle Foley
Michelle.Foley@moffitt.org
813-745-1505
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt, Sanford-Burnham and Florida Hospital create Personalized Medicine Partnership of Florida
2. Fibroblasts contribute to melanoma tumor growth, say Moffitt Cancer Center researchers
3. Moffitt Cancer Center researchers find potential target for treating metastatic cancer
4. Moffitt researchers will be strong participants in American Society of Hematology meeting
5. Moffitt Cancer Center researchers find MK1775 active against sarcomas
6. Moffitt Cancer Center researchers find men less willing to be screened for cancer
7. Moffitt Cancer Center researchers unravel biochemical factor important in tumor metastasis
8. Moffitt Cancer Center researchers find regulatory T-cell clue to help prevent GVHD
9. Moffitt Cancer Center researchers find more clues to causes of breast cancer
10. Moffitt researchers find possible key to preventing chemotherapy resistance in ovarian cancer
11. Moffitt Cancer Center researchers use new tool to counter multiple myeloma drug resistance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... , ... March 30, 2017 , ... According to the ... performed each year, putting it among the top 5 most popular minimally-invasive cosmetic procedures ... those million-plus procedures will be performed over the next 8-10 weeks. For anyone considering ...
(Date:3/30/2017)... ... March 30, 2017 , ... Nutrition Education for ... Dietetics (AND), will join nonprofit Seafood Nutrition Partnership (SNP) in presenting “Eating Heart ... to help nutrition educators and students inform consumers about the health benefits of ...
(Date:3/29/2017)... ... March 29, 2017 , ... ARI Network Services, Inc. (NASDAQ: ... co-op eligible dealer websites for its network of more than 650 U.S.-based dealers. Rhino, ... agricultural equipment including rotary and flail mowers and cutters, rear blades, post hole diggers, ...
(Date:3/29/2017)... ... ... Grass pollen is the main cause of hay fever in the United States, with an ... runs from May to July each year; with the worst time for sufferers being June ... balms ( http://www.haymax.us ) provide an effective defense against grass pollen; they are proven in ...
(Date:3/29/2017)... ... ... Sports Brand EXOUS Bodygear announced today a special sale price for the ... days of March, the price will be only $19.97. The EXOUS Bodygear 65cm ... (regular retail price $19.97). , The special promotional prices are to help individuals get ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Research and Markets has announced the addition of the ... report to their offering. ... Proton Therapy Market in Italy will double ... are currently three proton therapy centers in Italy ... Italy , the first patients were treated with proton beams ...
(Date:3/29/2017)... 2017  Providence Medical Technology, Inc., an innovator ... two industry veterans to the commercial leadership team.  ... to lead Global Marketing, and Michael Scott ... and Mr. Scott have over 40 years of ... joins the company with over 22 years of ...
(Date:3/29/2017)... , March 29, 2017  Glenmark Pharmaceuticals, ... for GSP 301, an investigational fixed-dose combination of ... mcg) administered twice-daily as a nasal spray being ... These results are from a recently completed Phase ... GSP 301 combination therapy versus mometasone, olopatadine or ...
Breaking Medicine Technology: